Anxiety, patient activation, and quality of life among stroke survivors prescribed smartwatches for atrial fibrillation monitoring.
Atrial fibrillation
Elderly
Smartwatches
Stroke
Wearables
Journal
Cardiovascular digital health journal
ISSN: 2666-6936
Titre abrégé: Cardiovasc Digit Health J
Pays: United States
ID NLM: 101771268
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
medline:
21
8
2023
pubmed:
21
8
2023
entrez:
21
8
2023
Statut:
epublish
Résumé
The detection of atrial fibrillation (AF) in stroke survivors is critical to decreasing the risk of recurrent stroke. Smartwatches have emerged as a convenient and accurate means of AF diagnosis; however, the impact on critical patient-reported outcomes, including anxiety, engagement, and quality of life, remains ill defined. To examine the association between smartwatch prescription for AF detection and the patient-reported outcomes of anxiety, patient activation, and self-reported health. We used data from the Pulsewatch trial, a 2-phase randomized controlled trial that included participants aged 50 years or older with a history of ischemic stroke. Participants were randomized to use either a proprietary smartphone-smartwatch app for 30 days of AF monitoring or no cardiac rhythm monitoring. Validated surveys were deployed before and after the 30-day study period to assess anxiety, patient activation, and self-rated physical and mental health. Logistic regression and generalized estimation equations were used to examine the association between smartwatch prescription for AF monitoring and changes in the patient-reported outcomes. A total of 110 participants (mean age 64 years, 41% female, 91% non-Hispanic White) were studied. Seventy percent of intervention participants were novice smartwatch users, as opposed to 84% of controls, and there was no significant difference in baseline rates of anxiety, activation, or self-rated health between the 2 groups. The incidence of new AF among smartwatch users was 6%. Participants who were prescribed smartwatches did not have a statistically significant change in anxiety, activation, or self-reported health as compared to those who were not prescribed smartwatches. The results held even after removing participants who received an AF alert on the watch. The prescription of smartwatches to stroke survivors for AF monitoring does not adversely affect key patient-reported outcomes. Further research is needed to better inform the successful deployment of smartwatches in clinical practice.
Sections du résumé
Background
UNASSIGNED
The detection of atrial fibrillation (AF) in stroke survivors is critical to decreasing the risk of recurrent stroke. Smartwatches have emerged as a convenient and accurate means of AF diagnosis; however, the impact on critical patient-reported outcomes, including anxiety, engagement, and quality of life, remains ill defined.
Objectives
UNASSIGNED
To examine the association between smartwatch prescription for AF detection and the patient-reported outcomes of anxiety, patient activation, and self-reported health.
Methods
UNASSIGNED
We used data from the Pulsewatch trial, a 2-phase randomized controlled trial that included participants aged 50 years or older with a history of ischemic stroke. Participants were randomized to use either a proprietary smartphone-smartwatch app for 30 days of AF monitoring or no cardiac rhythm monitoring. Validated surveys were deployed before and after the 30-day study period to assess anxiety, patient activation, and self-rated physical and mental health. Logistic regression and generalized estimation equations were used to examine the association between smartwatch prescription for AF monitoring and changes in the patient-reported outcomes.
Results
UNASSIGNED
A total of 110 participants (mean age 64 years, 41% female, 91% non-Hispanic White) were studied. Seventy percent of intervention participants were novice smartwatch users, as opposed to 84% of controls, and there was no significant difference in baseline rates of anxiety, activation, or self-rated health between the 2 groups. The incidence of new AF among smartwatch users was 6%. Participants who were prescribed smartwatches did not have a statistically significant change in anxiety, activation, or self-reported health as compared to those who were not prescribed smartwatches. The results held even after removing participants who received an AF alert on the watch.
Conclusion
UNASSIGNED
The prescription of smartwatches to stroke survivors for AF monitoring does not adversely affect key patient-reported outcomes. Further research is needed to better inform the successful deployment of smartwatches in clinical practice.
Identifiants
pubmed: 37600446
doi: 10.1016/j.cvdhj.2023.04.002
pii: S2666-6936(23)00027-0
pmc: PMC10435956
doi:
Types de publication
Journal Article
Langues
eng
Pagination
118-125Informations de copyright
© 2023 Heart Rhythm Society.
Références
Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
Cardiovasc Digit Health J. 2020 Jul-Aug;1(1):9-10
pubmed: 34386784
N Engl J Med. 2019 Nov 14;381(20):1909-1917
pubmed: 31722151
IEEE Trans Biomed Eng. 2013 Jan;60(1):203-6
pubmed: 22868524
Ann Intern Med. 2007 Jun 19;146(12):857-67
pubmed: 17577005
Med Decis Making. 2018 Apr;38(3):334-343
pubmed: 29436308
Sci Rep. 2019 Oct 21;9(1):15054
pubmed: 31636284
Circ Res. 2020 Jun 19;127(1):128-142
pubmed: 32716695
JAMA. 2021 Jun 1;325(21):2160-2168
pubmed: 34061146
J Am Coll Cardiol. 2018 Jun 12;71(23):2691-2701
pubmed: 29880130
Circulation. 2022 Nov 8;146(19):1415-1424
pubmed: 36148649
Nat Rev Neurol. 2016 May;12(5):269-80
pubmed: 27063107
Circulation. 2019 Jul 9;140(2):e125-e151
pubmed: 30686041
Cardiovasc Digit Health J. 2022 Apr 18;3(3):126-135
pubmed: 35720675
Health Qual Life Outcomes. 2018 Feb 13;16(1):34
pubmed: 29439718
Cardiovasc Digit Health J. 2021 Jul 13;2(4):231-241
pubmed: 35265913
Circ Arrhythm Electrophysiol. 2009 Oct;2(5):474-80
pubmed: 19843914
Cardiovasc Digit Health J. 2022 Aug 03;3(5):198-200
pubmed: 36310684
AMIA Annu Symp Proc. 2021 Jan 25;2020:213-222
pubmed: 33936393
Circulation. 2022 Feb 22;145(8):e153-e639
pubmed: 35078371
Cardiovasc Digit Health J. 2021 Mar 04;2(2):92-100
pubmed: 35265896
Cardiovasc Digit Health J. 2020 Jul-Aug;1(1):21-29
pubmed: 32924024